This book highlights the role and mechanism of different metal nanocomposites toward oxidative stress-induced metabolic disorders including metabolic pathways affected by oxidative stress and related pathophysiology. The book includes an illustrative discussion about the methods of synthesis, characterization, and biomedical applications of metal nanocomposites. It focuses on the therapeutic approaches for metabolic disorders due to oxidative stress by nano delivery systems. Moreover, the book includes chapters on nanotherapeutic approaches toward different diseases, including diabetes mellitus, obesity, cardiovascular disorders, cancers, and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. This book is aimed at researchers and graduate students in nanocomposites, nano delivery systems, and bioengineering.
Features
Discusses nanocomposites in the field of therapy for diabetes, obesity, cardiovascular disorders, neurodegenerative diseases, and cancers
Details the pathophysiology of oxidative stress-induced metabolic disorder
Explains mechanisms of the antioxidant potential of metal nanocomposites
Discusses pathways to elucidate the therapeutic activity
Reviews specific and precise applications of metal nanocomposites against lifestyle-induced disorders
Chapter 1. Oxidative stress-induced metabolic disorders: Mechanism and pathogenesis1.1. Introduction 1.2. Metabolic diseases and oxidative stress 1.3. Oxidative stress and metabolic disorder leading to diabetes 1.4. Oxidative stress leading to CVD 1.5. Oxidative stress resulting in carcinogenesis 1.6. Oxidative stress leading to obesity 1.7. Conclusion and Future Prospects References Chapter 2. Metal nanocomposites: synthesis, characterization, and biomedical applications 2.1. Introduction 2.2. Historical Background 2.3. Properties of Nanocomposites 2.4. Classification of Nanocomposites 2.5. Emerging trends in the Metal Oxide nanocomposites 2.6. Fabrication of the Metal Oxide Nanocomposites 2.7. Characterization of the fabricated Metal Oxide Nanocomposites 2.8. Factors influencing the fabrication and characterization of Metal Oxide Nanocomposites 2.9. Biomedical applications of the Metal Oxide Nanocomposites in oxidative stress-induced disorders 2.10. Challenges and Limitations of the Metal Oxide Nanocomposites 2.11. Conclusion and Future perspectives References Chapter 3. The general concept of metal nanocomposites in nanotherapeutics against oxidative stress-induced metabolic disorders3.1. Nanotherapeutics and Nanocomposites 3.2. Oxidative stress (OS)-induced metabolic disorders (MD) 3.3. Role of metal nanocomposites in theranostic and management of OS-induced metabolic disorders 3.4. Conclusion and future perspectives of MNCs References Chapter 4. Nanotherapeutics for leptin resistance and obesity using metal nanocomposites4.1. Introduction 4.2. Pathophysiology of leptin resistance and obesity 4.3. Relation between oxidative stress and Obesity 4.4. Pharmacological Treatment of Obesity and challenges 4.5. Theranostic applications of metal nanocomposites in leptin resistance and obesity 4.6. Conclusion and future perspectives References Chapter 5. Nanotherapeutics for insulin resistance and diabetes mellitus using metal nanocomposites 5.1 Diabetes Mellitus (DM) and Insulin Resistance 5.2 Mechanisms of Insulin Resistance and Diabetes caused by Oxidative Stress 5.3 Diagnosis of Diabetes Mellitus 5.4 Metal-based Nanosensors in Diagnosis of Diabetes Mellitus 5.5 Treatment of Diabetes Mellitus and Insulin Resistance 5.6 Conclusion and Future prospectives References Chapter 6. Nanotherapeutics for diabetic retinopathy with metal nanocomposites 6.1. Introduction 6.2. Anatomy and Physiology of Retina 6.3. Pathophysiology of Diabetic Retinopathy 6.4. Treatment 6.5. Drawbacks of conventional therapy 6.6. Metal nanocomposites 6.7. Applications of Metal nanocomposites in DR 6.8. Recent advances and future perspectives 6.9. Conclusions References Chapter 7. Nanotherapeutics for diabetic nephropathy with metal nanocomposites 7.1. Introduction 7.2. Metal nanocomposites in diabetic nephropathy 7.3. Future perspectives 7.4. Conclusion References Chapter 8. Nanotherapeutics for diabetic cardiomyopathy using metal nanocomposites 8.1. Introduction 8.2. Signaling pathways of DCM 8.3. Current therapeutic implications and challenges in DCM 8.4. Nanomaterials as drug therapy for diabetic cardiomyopathy 8.5. Recent trends in the treatment of DCM with nanocomposites 8.6. Challenges, Limitations, and Future Prospectives 8.7. Conclusion References Chapter 9. Nanotherapeutics for a diabetic foot ulcer and wound healing with metal nanocomposites 9.1. Diabetic foot ulcer and wound healing 9.2. Design of metal nanocomposites and their applications in wound healing 9.3. Biocompatibility of metal nanocomposites 9.4. Patents on metal nanocomposites for DFU and wound healing 9.5. Current challenges and prospects 9.6. Conclusion References Chapter 10. Nanotherapeutics for management of dyslipidemia 10.1. Introduction 10.2. Etiopathogenesis of dyslipidemia 10.3. Management of dyslipidemia 10.4. Plant-based drugs for dyslipidemia 10.5. Nanotherapeutics for dyslipidaemia 10.6. ROS-based nanotherapeutics against dyslipidaemia 10.7. Conclusion References Chapter 11. Nanotherapeutics for endometrial cancer with metal nanocomposites 11.1 Introduction 11.2 Molecular mechnism of endometrial cancer 11.3 Recent Difficulties in Endometrial Cancer Treatment 11.4 Future Treatment Approaches in Endometrial Cancer: Metalloproteinase Inhibitors 11.5 Nanomedicines and cancer treatments based on glycans 11.6 Nanocomposites of Polymers and Metals in the Treatment of Endometrial Cancer 11.7 Conclusion References Chapter 12. Nanotherapeutics for colorectal cancer using metal nanocomposites 12.1. Introduction 12.2. Cancer Cell Biology: Exploiting Deviant Physiological Features 12.3. Metal/Carbon Nanoparticles in Microbot/Nanobot design 12.4. Synthetic Strategies for Nanocomposites 12.5. Colorectal Cancer Models 12.6. Strategies of Colorectal Cancer Cell/Tumor Targeting 12.7. Conclusions and Path Forward References Chapter 13. Nanotherapeutics for ovarian cancer using metal nanocomposites 13.1. Introduction 13.2. Pathogenesis of Ovarian cancer 13.3. Challenges with current therapy for ovarian cancer treatment 13.4. Classification and Applications of metal nanocomposites 13.5. Benefits of metal nanocomposites in treating ovarian cancer 13.6. Challenges in using metal nanocomposites for ovarian cancer 13.7. Adverse effects/toxicities associated with the use of metal nanocomposites 13.8. Conclusion and Future Perspectives References Chapter 14. Nanotherapeutics for breast cancer using metal nanocomposites 14.1. Introduction 14.2. Conventional treatment for breast cancer 14.3. Nanotechnology-based approaches to treat breast cancer 14.4. Different nano-formulations for the Therapy of breast cancer 14.5. Metal Nanocomposites for Breast Cancer 14.6. Role of metal nanocomposites in breast cancer treatment 14.7. Conclusion References Chapter 15. Nanotherapeutics for liver cancer with metal nanocomposites15.1. Introduction 15.2. Biocompatibility and Toxicity of Nanocomposites 15.3. Nano-antioxidants 15.4. Macromolecular Nanocomposites 15.5. Targeting Nanocomposites to HCC 15.6. Nanocomposites in the Therapy of HCC 15.7. Limitations of Nanocomposites 15.8. Conclusions Reference Chapter 16. Nanotherapeutics for reversal against multidrug resistance in chemotherapy with metal nanocomposites 16.1 Introduction 16.2 Nanotherapeutics 16.3 Metal Nanocomposites 16.4 Metal Oxide Nanocomposites: 16.5 Conclusion References Chapter 17. Nanotherapeutics for Alzheimer’s disease using metal nanocomposites17.1. Introduction 17.2. Role of Metal nanocomposites in neurodegeneration: From inception to treatment 17.3. Metal nanocomposites utilized in the detection and treatment of Alzheimer's disease 17.4. Conclusion References Chapter 18. Nanotherapeutics for PD using metal nanocomposites 18.1. Background 18.2. Pathophysiology of PD 18.3. Current therapeutics for PD 18.4. Nanotherapeutics: A promising approach in the treament of PD 18.5. Applications of metal nanocomposites for PD 18.6. Conclusion References
Anindita Behera is an Associate Professor, Department of Pharmaceutical Analysis, Siksha ‘O’ Anusandhan Deemed to be University. She did her masters from Pune University, India, and Ph.D. from Siksha ‘O’ Anusandhan Deemed to be University. She has developed new analytical methods for drug formulations used in the treatment of AIDS. Currently, she is involved in the green synthesis of nanomaterial targeting different life-risk diseases. She has more than 15 years of experience in research and academics. She has published several research and review articles in peer-reviewed journals. She has also contributed many book chapters to books published with other leading publishers. She has guided two Ph.D. scholars; eleven post-graduate scholars and 30 undergraduate students.
